Elder Pharma is currently trading at Rs. 307.00, up by 4.30 points or 1.42% from its previous closing of Rs. 302.70 on the BSE.
The scrip opened at Rs. 310.00 and has touched a high and low of Rs. 311.00 and Rs. 300.00 respectively. So far 794 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 474.00 on 05-Dec-2012 and a 52 week low of Rs. 267.05 on 16-Aug-2012.
Last one week high and low of the scrip stood at Rs. 323.90 and Rs. 296.00 respectively. The current market cap of the company is Rs. 625.56 crore.
The promoters holding in the company stood at 39.89% while Institutions and Non-Institutions held 22.92% and 37.18% respectively.
Elder Pharmaceuticals, a leading pharmaceuticals company in India, has formed a joint venture (JV) ‘Kose Elder (India)’ with Japan’s Kose Corporation to manufacture and sell cosmetics in India. The company will hold 40% stake in the JV while Kose Corporation will hold 60% stake.
The JV will manufacture all kinds of skin care products including creams, lotions and ointment. Besides, Kose products will be produced in the existing plant of Elder Pharmaceuticals in Paonta Sahib in Himachal Pradesh.
Elder Pharmaceuticals (EPL) has around six manufacturing units in India, all as per international standards. Post increasing its stake in Elder Biomeda AD and Neutrahealth PLC, EPL also has access to the manufacturing units of these companies in Bulgaria and Birmingham, UK respectively coupled with distribution network and brands of the same.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: